- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2261
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Short-term LDL cholesterol-lowering efficacy of plant stanol esters ; volume:2 ; number:1 ; day:27 ; month:8 ; year:2002 ; pages:1-7 ; date:12.2002
BMC cardiovascular disorders ; 2, Heft 1 (27.8.2002), 1-7, 12.2002
- Urheber
-
Hallikainen, Maarit
- Beteiligte Personen und Organisationen
-
Sarkkinen, Essi
Wester, Ingmar
Uusitupa, Matti
SpringerLink (Online service)
- DOI
-
10.1186/1471-2261-2-14
- URN
-
urn:nbn:de:1111-2016030244187
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hallikainen, Maarit
- Sarkkinen, Essi
- Wester, Ingmar
- Uusitupa, Matti
- SpringerLink (Online service)
Ähnliche Objekte (12)
Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Cholesterol-Lowering Super juice
Overcoming therapeutic inertia in LDL cholesterol-lowering treatment with education and simplified treatment algorithms
Quo vadis, LDL cholesterol?
Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
A Retrospective Cohort Study of the Potency of lipid-lowering therapy and Race-gender Differences in LDL cholesterol control
Cholesterol lowering: role in cancer prevention and treatment
2024 Egyptian consensus statement on the role of non-statin therapies for LDL cholesterol lowering in different patient risk categories
Studien zur Bindungscharakteristik von Cholesterol bzw. LDL an verschiedene Chargen LDL-adsorbierender Perlzellulose
Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Cholesterol-Lowering Super juice
Overcoming therapeutic inertia in LDL cholesterol-lowering treatment with education and simplified treatment algorithms
Quo vadis, LDL cholesterol?
Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
A Retrospective Cohort Study of the Potency of lipid-lowering therapy and Race-gender Differences in LDL cholesterol control
Cholesterol lowering: role in cancer prevention and treatment
2024 Egyptian consensus statement on the role of non-statin therapies for LDL cholesterol lowering in different patient risk categories
Studien zur Bindungscharakteristik von Cholesterol bzw. LDL an verschiedene Chargen LDL-adsorbierender Perlzellulose
Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Cholesterol-Lowering Super juice
Overcoming therapeutic inertia in LDL cholesterol-lowering treatment with education and simplified treatment algorithms
Quo vadis, LDL cholesterol?
Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
A Retrospective Cohort Study of the Potency of lipid-lowering therapy and Race-gender Differences in LDL cholesterol control
Cholesterol lowering: role in cancer prevention and treatment
2024 Egyptian consensus statement on the role of non-statin therapies for LDL cholesterol lowering in different patient risk categories